Home » Topics » BioWorld Science

BioWorld Science
RSS

FDA clears Fusion's IND applications for FPI-2059 and imaging analogue FPI-2058

June 27, 2022

Dual CXCR4/ACKR3 inhibitor in combination with ICT impedes 4T1 tumor growth and metastasis

June 27, 2022

Silo in commercial evaluation license agreement for next-generation liposomes for autoimmune disease

June 27, 2022

Tokyo University of Science discloses LXR antagonists

June 27, 2022

Merck & Co. identifies new GLCT-1 inhibitors

June 27, 2022

SAGE Therapeutics describes new GABA-A receptor modulators

June 27, 2022

Anti-HER2 domain-specific antibody-drug radioconjugates show promise in models of breast cancer

June 27, 2022

Sumitomo Pharma divulges Chk1 inhibitors

June 27, 2022

Servier patents new MAT2A inhibitors

June 27, 2022

Novel murine model may shed light for future strategies for aggressive glioblastoma

June 27, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...